Skip to main content

Table 3 Therapy change based on receptor status in 24 patients

From: Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)

Primary

Recurrence

Primary PR

Recurrence PR

Primary ER

Recurrence ER

Primary HER2

Recurrence HER2

Therapy change based on

Excision

Core

7

8

7

8

Positive

Negative

HER2

Excision

Core

7

7

8

8

Negative

Positive

HER2

Excision

Core

7

6

8

8

Negative

Positive

HER2

Excision

Excision

0

0

7

0

Negative

Positive

ER and HER2

Excision

Excision

0

0

7

0

Negative

Negative

ER

Excision

Excision

0

0

3

2

Negative

Negative

ER

Excision

Core

7

3

6

0

Negative

Negative

ER

Excision

Excision

8

0

7

0

Negative

Negative

ER

Excision

Excision

0

0

8

0

Negative

Negative

ER

Excision

Core

2

2

7

0

Negative

Negative

ER

Excision

Excision

5

0

6

2

Negative

Negative

ER

Excision

Excision

0

0

3

0

Positive

Positive

ER

Excision

Excision

4

0

7

0

Positive

Positive

ER

Excision

Excision

0

0

0

7

Negative

Negative

ER

Excision

Excision

0

6

0

8

Negative

Negative

ER

Excision

Excision

0

0

0

7

Negative

Negative

ER

Excision

Excision

6

0

8

2

Positive

Positive

ER and PR

Excision

Excision

4

0

0

0

Negative

Negative

PR

Core

Excision

5

0

0

0

Negative

Negative

PR

Core

Core

6

0

8

7

Negative

Negative

PR

Excision

Excision

6

0

7

7

Negative

Negative

PR

Excision

Excision

7

0

7

7

Negative

Negative

PR

Excision

Excision

7

0

7

7

Negative

Negative

PR

Excision

Excision

4

0

6

5

Negative

Negative

PR

  1. Comparison of primary and recurrent breast cancer progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor type 2 (HER2) with documented reason for change in subsequent therapy is shown. Receptor status is summarized as negative (-) or positive (+).